BCR ABL 1 Kinase Domain Mutation Analysis
This test detects mutations in the kinase domain of the BCR-ABL gene, which may indicate resistance to certain leukemia treatments. It helps guide therapy choices in chronic myelogenous leukemia (CML).
Overview of BCR ABL 1 Kinase Domain Mutation Analysis in Nagercoil
What is the BCR-ABL Kinase Domain Mutation Analysis?
This test detects mutations in the kinase domain of the BCR-ABL fusion gene, which can cause resistance to tyrosine kinase inhibitors (TKIs) used in treating chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).
Who should get this test?
Patients with CML or Philadelphia chromosome-positive ALL who are not responding to TKIs.
Individuals experiencing disease relapse after TKI treatment.
Monitoring for drug resistance in long-term therapy.
How is the test performed?
A blood or bone marrow sample is analyzed using PCR and sequencing methods to identify mutations in the BCR-ABL gene.
What do the results indicate?
Mutations detected: May suggest resistance to certain TKIs, requiring a change in treatment.
No mutations detected: The treatment may need to be adjusted due to other factors, not mutations.
Why is this test important?
Identifying mutations in BCR-ABL helps determine the most effective therapy and prevent disease progression.
Test included
- Specimen
- Bcr-abl 1 Kinase Domain Mutations
Doctor information
Test code
5351
CPT and Loinc codes
Department
- Advanced Molecular Diagnostics R&d
Turn around time
10 Working Days
Test run frequency
Every Day TIME - 10:00
Performing locations
1 labs across India
Specimen vol. and vacutainer information
| Specimen | Vacutainer | Volume |
|---|---|---|
| Edta Whole Blood | Lavender Vacutainer | 3 ML |
Specimen stability information
Edta Whole Blood
Test price
₹10710
Need Help?
Talk to our health experts for guidance on tests, reports, or bookings.
WhatsApp to Book TestBCR ABL 1 Kinase Domain Mutation Analysis
₹10710